NCT06880029View on ClinicalTrials.gov

Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2025

Conditions
Triple Negative Breast Cancer (TNBC)
Interventions
OTHER

Morning pembrolizumab infusions

Patients will be randomized 1:1 to receive all three neoadjuvant pembrolizumab cycles in the morning (before noon) or in the afternoon (after noon).

Trial Locations (1)

4434-502

RECRUITING

Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia

All Listed Sponsors
lead

Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.

OTHER_GOV